Video

Introducing ioGlutamatergic Neurons HTT 50CAG/WT™ | A next-generation approach to study Huntington's disease

Watch this video to learn about the exciting first product from bit.bio’s new ioDisease Model portfolio, ioGlutamatergic Neurons HTT 50CAG/WT for Huntington’s disease research and drug discovery.
Introducing ioGlutamatergic Neurons HTT 50CAG/WT™ | A next-generation approach to study Huntington's disease

Dr Tony Oosterveen | Senior Scientist 
bit.bio

HubSpot Video
Watch this video to learn about the exciting first product from bit.bio’s new ioDisease Model portfolio, ioGlutamatergic Neurons HTT 50CAG/WT for Huntington’s disease research and drug discovery.
Introducing ioGlutamatergic Neurons HTT 50CAG/WT™ | A next-generation approach to study Huntington's disease

Dr Tony Oosterveen | Senior Scientist 
bit.bio

In this video, you will learn about the development of the human iPSC-derived glutamatergic neurons with a 50 CAG repeat expansion, the power of opti-ox powered disease models and the benefit of using genetically matched controls in the study of Huntington’s disease.

The bit.bio team offers insights into the industry-leading consistency and scalability of ioGlutamatergic Neurons HTT 50CAG/WT and the potential impact the disease model has on Huntington's disease research and drug discovery.

Find out more about the characterisation of our Huntington’s disease model in the brochure here.

2022

Dr Tony Oosterveen | Senior Scientist
Dr Zoe Nilsson | Global Product Marketing Manager
Ben Newman | Scientist

bit.bio

Related pages

News Read our latest updates and press coverage
Our platform Discover the cell identity coding platform behind our cells
Join us Explore the latest roles at bit.bio